NeuVax

Nov 27, 2018

Generex Biotechnology Signs Clinical Trial Agreement With the NSABP Foundation, Inc. for Phase II Clinical Trial of AE37 in Combination With Pembrolizumab (Keytruda®) for Treatment of Triple-Negative Breast Cancer

Aug 31, 2018

The Growing Demand for Cancer Treatment is Raising Immunotherapy Dependence

Apr 04, 2018

Small Cap to Large Cap Pharma Companies Positioning to Capitalize on Resurgent Biotech Industry

Dec 12, 2017

TapImmune Announces Enrollment of First Patient in Phase 2 Clinical Trial for Treating Triple-Negative Breast Cancer Funded by U.S. Department of Defense

Nov 14, 2017

TapImmune Completes Patient Enrollment Ahead of Schedule in Phase 2 Cancer Vaccine Study for Treating Triple-Negative Breast Cancer

Jun 27, 2017

TapImmune Reaches 50% Patient Enrollment Benchmark in Phase 2 Study of Novel T-Cell Vaccine Targeting Triple-Negative Breast Cancer

May 31, 2017

TapImmune Provides First Quarter 2017 Corporate and Clinical Update